Top

Published in:

Open Access 01-12-2017 | Editorial

Inflammasome lights up in systemic sclerosis

Authors: John Henderson, Steven O’Reilly

Published in: Arthritis Research & Therapy | Issue 1/2017

Abstract

Systemic sclerosis (SSc) is a pro-fibrotic condition with a poorly understood aetiology. Evidence presented by Artlett et al. in this issue suggests that the microRNA miR-155 is key, with its involvement dependent on the NLRP3 inflammasome. This links epigenetic events with inflammasome signalling in SSc and opens the door to new therapeutic strategies for the treatment of SSc.

Artlett CM, Sassi-Gaha S, Hope JL, Feghali-Bostwick CA, Katsikis PD. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 2017;19:144. doi:10.1186/s13075-017-1331-z.CrossRefPubMedPubMedCentral

O’Reilly S. MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther. 2016;18:11. doi:10.1186/s13075-016-0929-x.CrossRefPubMedPubMedCentral

Yan Q, Chen J, Li W, Bao C, Fu Q. Targeting miR-155 to treat experimental scleroderma. Sci Rep. 2016;6:20314. doi:10.1038/srep20314.CrossRefPubMedPubMedCentral

Abtahi S, Farazmand A, Mahmoudi M, Ashraf-Ganjouei A, Javinani A, Nazari B, et al. IL-1A rs1800587, IL-1B rs1143634 and IL-1R1 rs2234650 polymorphisms in Iranian patients with systemic sclerosis. Int J Immunogenet. 2015;42(6):423–7. doi:10.1111/iji.12212.CrossRefPubMed

Coll RC, Robertson AAB, Chae JJ, et al. A small molecule inhibitor of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases. Nat Med. 2015;21(3):248–55. doi:10.1038/nm.3806.PubMedPubMedCentral

Duan NN, Liu XJ, Wu J. Palmitic acid elicits hepatic stellate cell activation through inflammasomes and hedgehog signaling. Life Sci. 2017;176:42–53. doi:10.1016/j.lfs.2017.03.012.CrossRefPubMed

Title: Inflammasome lights up in systemic sclerosis
Authors: John Henderson
Steven O’Reilly
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/s13075-017-1420-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Inflammasome lights up in systemic sclerosis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis

Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT)

Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study

Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page